LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)

Authors: Sherene Loi, Giuseppe Curigliano, Roberto Salgado, Roberto Iván Romero Díaz, Suzette Delaloge, C. Rojas, Marleen Kok, C. Saura Manich, Nadia Harbeck, Elizabeth A. Mittendorf, Denise A. Yardley, Lajos Pusztai, Alberto Suárez Zaizar, Aurelian Ungureanu, Felipe Ades, R. Chandra, Raheel Nathani, Misena Pacius, Jintong Wu, Heather L. McArthur - Annals of Oncology 2023 cited by 103